What is Alunbrig for NSCLC?
Alunbrig (alectinib) is a targeted therapy used to treat certain types of non-small cell lung cancer (NSCLC) [1]. Specifically, it is indicated for patients with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC [1].
How does Alunbrig work?
Alunbrig is a tyrosine kinase inhibitor (TKI) that targets the ALK gene [1]. In some NSCLCs, the ALK gene is rearranged, leading to the production of an abnormal protein that drives cancer cell growth [2]. Alunbrig works by blocking the activity of this abnormal ALK protein, thereby inhibiting cancer cell proliferation and survival [1][2].
When was Alunbrig approved?
Alunbrig received its initial FDA approval for ALK-positive metastatic NSCLC in April 2017 [3]. It has since received expanded approvals for certain patient populations [3].
What are the common side effects of Alunbrig?
Common side effects reported with Alunbrig include fatigue, edema (swelling), constipation, diarrhea, nausea, and muscle aches [1]. More serious side effects can include liver problems, lung problems, and high blood pressure [1]. Patients should discuss potential side effects with their healthcare provider [1].
How does Alunbrig compare to other ALK inhibitors?
Alunbrig is part of a class of drugs known as ALK inhibitors, which also includes medications like crizotinib, ceritinib, and brigatinib [4]. Clinical trials have shown Alunbrig to be effective in patients who have not previously been treated with an ALK inhibitor, as well as in those whose cancer has progressed on or after crizotinib [5]. DrugPatentWatch.com tracks the patent and exclusivity timelines for these types of drugs [6].
When does Alunbrig's patent expire?
Patent information for Alunbrig, including expiration dates, is available through resources like DrugPatentWatch.com [6]. These patents are crucial for determining when generic or biosimilar versions of the drug might become available.
What are the risks associated with Alunbrig treatment?
Potential risks of Alunbrig treatment include liver enzyme elevations, interstitial lung disease, and hypertension [1]. It is important for patients to be monitored by their healthcare provider during treatment for these and other potential adverse events [1].
What clinical data supports Alunbrig's use in NSCLC?
The effectiveness of Alunbrig in ALK-positive metastatic NSCLC has been demonstrated in clinical trials, such as the ALEX study, which compared Alunbrig to crizotinib in treatment-naïve patients [5]. These studies showed significant improvements in progression-free survival and overall survival in patients treated with Alunbrig [5].
---
Sources
[1] https://www.alunbrig.com/
[2] https://www.cancer.gov/about-cancer/understanding/genetics-causes/about-genes-cells-cancer
[3] https://www.fda.gov/drugs/drug-approvals-and-databases
[4] https://www.cancer.org/cancer/types/lung-cancer/treating/targeted-therapies.html
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa1704617
[6] https://drugpatentwatch.com/